Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

@article{Brufsky2018EstrogenRB,
  title={Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.},
  author={Adam M. Brufsky and Maura N. Dickler},
  journal={The oncologist},
  year={2018},
  volume={23 5},
  pages={
          528-539
        }
}
  • Adam M. Brufsky, Maura N. Dickler
  • Published in The oncologist 2018
  • Medicine
  • Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded our understanding of breast cancer (BC) pathogenesis and hold promising implications for the future of therapy. The estrogen receptor-α is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. Successful targeting of proteins and genes within estrogen receptor (ER) nuclear and nonnuclear pathways remains a… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    1
    Twitter Mention

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 12 CITATIONS

    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

    VIEW 7 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Analysis of status and countermeasures of cancer incidence and mortality in China

    VIEW 2 EXCERPTS
    CITES BACKGROUND & METHODS